These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37545504)

  • 1. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.
    Gadiyar V; Patel G; Chen J; Vigil D; Ji N; Campbell V; Sharma K; Shi Y; Weiss MM; Birge RB; Davra V
    Front Immunol; 2023; 14():1135373. PubMed ID: 37545504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis.
    Gao L; He C; Yang A; Zhou H; Lu Q; Birge RB; Wu Y
    Cell Commun Signal; 2023 Aug; 21(1):195. PubMed ID: 37537628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
    Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
    Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation.
    Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y
    Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
    McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
    Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
    Myers KV; Amend SR; Pienta KJ
    Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers.
    Grabiec AM; Goenka A; Fife ME; Fujimori T; Hussell T
    Eur J Immunol; 2018 May; 48(5):855-860. PubMed ID: 29400409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.
    Kasikara C; Kumar S; Kimani S; Tsou WI; Geng K; Davra V; Sriram G; Devoe C; Nguyen KN; Antes A; Krantz A; Rymarczyk G; Wilczynski A; Empig C; Freimark B; Gray M; Schlunegger K; Hutchins J; Kotenko SV; Birge RB
    Mol Cancer Res; 2017 Jun; 15(6):753-764. PubMed ID: 28184013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
    Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
    Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonistic Coevolution of MER Tyrosine Kinase Expression and Function.
    Evans AL; Blackburn JWD; Taruc K; Kipp A; Dirk BS; Hunt NR; Barr SD; Dikeakos JD; Heit B
    Mol Biol Evol; 2017 Jul; 34(7):1613-1628. PubMed ID: 28369510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.
    Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB
    J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
    Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
    Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
    Branchford BR; Stalker TJ; Law L; Acevedo G; Sather S; Brzezinski C; Wilson KM; Minson K; Lee-Sherick AB; Davizon-Castillo P; Ng C; Zhang W; Neeves KB; Lentz SR; Wang X; Frye SV; Shelton Earp H; DeRyckere D; Brass LF; Graham DK; Di Paola JA
    J Thromb Haemost; 2018 Feb; 16(2):352-363. PubMed ID: 29045015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase.
    Kimani SG; Kumar S; Davra V; Chang YJ; Kasikara C; Geng K; Tsou WI; Wang S; Hoque M; Boháč A; Lewis-Antes A; De Lorenzo MS; Kotenko SV; Birge RB
    Cell Commun Signal; 2016 Sep; 14(1):19. PubMed ID: 27595981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
    Peeters MJW; Rahbech A; Thor Straten P
    Cancer Immunol Immunother; 2020 Feb; 69(2):237-244. PubMed ID: 31664482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage AXL receptor tyrosine kinase inflames the heart after reperfused myocardial infarction.
    DeBerge M; Glinton K; Subramanian M; Wilsbacher LD; Rothlin CV; Tabas I; Thorp EB
    J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33529176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation.
    Tsou WI; Nguyen KQ; Calarese DA; Garforth SJ; Antes AL; Smirnov SV; Almo SC; Birge RB; Kotenko SV
    J Biol Chem; 2014 Sep; 289(37):25750-63. PubMed ID: 25074926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours.
    Dave F; Herrera K; Lockley A; van de Weijer LL; Henderson S; Sofela AA; Hook L; Adams CL; Ercolano E; Hilton DA; Maze EA; Kurian KM; Ammoun S; Hanemann CO
    Oncogene; 2024 Oct; 43(41):3049-3061. PubMed ID: 39179860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of the functionally elusive TAM receptor family.
    Miao YR; Rankin EB; Giaccia AJ
    Nat Rev Drug Discov; 2024 Mar; 23(3):201-217. PubMed ID: 38092952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells.
    Seitz HM; Camenisch TD; Lemke G; Earp HS; Matsushima GK
    J Immunol; 2007 May; 178(9):5635-42. PubMed ID: 17442946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.